Wells Fargo maintains Amphastar Pharma at Equal-Weight, raises price target to $25 from $20
Wells Fargo kept Amphastar Pharma at Equal-Weight, raising its price target to $25 from $20, suggesting a 9.6% downside from the Nov 5 close of $27.66.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short-term selling but could be outweighed by company-specific catalysts.
Market read
A modest analyst downgrade with a new lower price target; limited immediate trading impact.
What to watch
Potential upcoming clinical data or FDA decisions could offset the analyst's bearish stance.
Background
Wells Fargo's target adjustment is part of its regular coverage updates for small-cap biotech firms.
Ticker impact
Wells Fargo raised its price target for Amphastar Pharma to $25 from $20, implying a downside from the current price.
likely pressure as the market prices in the lower target
The new target is below the recent close, indicating a bearish view from a major broker.
Market effects
Minimal impact on the broader biotech sector; only reflects one broker's view.
Limited to U.S. markets where AMPH trades.
Low
Counterpoint
Investors may view the lower target as a buying opportunity if they disagree with the downgrade.
Key entities
- AnalystWells Fargo
Broker raising price target for Amphastar Pharma.
- CompanyAmphastar Pharma
Biotech firm whose stock is being re-evaluated.
